Pharmac proposal to fund FreeStyle Libre 2 for all people with type 1 diabetes in New Zealand 

On 11 July 2023, Pharmac released a Request for Proposals (RFP) for the supply of insulin pumps, consumables and CGMs. As a result of the RFP, Pharmac has entered into provisional agreements with preferred suppliers (including Abbott) to fund a range of devices.

 

Following a public consultation period in April 2024, on 21 May 2024 Pharmac shared an update on the proposal:

“We received a significant amount of feedback on our proposal, which reflects how important these devices are to people living with type 1 diabetes, their whānau, and clinicians. Thank you for sharing your views and experiences with us.

We have identified aspects of the proposal that we need to consider further. This means that the timeframe for making CGMs available, if approved by the Pharmac Board, will be pushed back.

At this point we can’t provide a definitive timeframe for when a decision will be made. We are working on this as a priority to enable a decision to be made as soon as possible. Pharmac is committed to progressing this proposal.”

Source: https://pharmac.govt.nz/news-and-resources/news/cgms

 

Pharmac have indicated their commitment to progressing this proposal and Abbott are working with Pharmac to support subsidised access to FreeStyle Libre CGM products as soon as possible.

Pharmac online information session: Thursday 6 June

Pharmac will host an online information session to talk about the process of developing the funding proposal and provide an update on Pharmac’s next steps, including engagement with clinicians, consumers and suppliers.

Details of information session:
• 12.00pm - 12.45pm, Thursday 6 June 2024
• Session will be online on Microsoft Teams. Attendees will not need an account to join
• The session will be recorded and available on Pharmac’s website afterwards

Please click HERE to visit the Pharmac website for the link to the online session

 

Keep in touch for important updates

To register for updates from Mediray on the proposed FreeStyle Libre 2 CGM subsidy, please click the button below:

Sign up

 

The FreeStyle Libre Flash Glucose Monitoring System and the FreeStyle Libre 2 Flash Glucose Monitoring system is indicated for measuring interstitial fluid glucose levels in people (aged 4 and older) with insulin-dependent diabetes. The indication for children (age 4 – 17) is limited to those who are supervised by a caregiver who is at least 18 years of age. Always read the instructions for use. The system must not be used with automated insulin dosing (AID) systems, including closed-loop and insulin suspend systems. The sensor must be removed prior to Magnetic Resonance Imaging (MRI).

The sensor housing, FreeStyle, Libre and related brand marks are marks of Abbott. Information contained herein is for distribution outside of the USA only. ADC-93688 V1.0